Advances in the management of malignancy-associated hyperuricaemia
1998

Advances in Managing High Uric Acid Levels in Cancer Patients

Sample size: 28 publication Evidence: moderate

Author Information

Author(s): HH Mahmoud, G Leverger, C Patte, E Harvey, F Lascombes

Primary Institution: Service d'Hematologie et d'Oncologie, Hopital d'Enfants Armand Trousseau, Paris, France

Hypothesis

Is the recombinant urate oxidase SR29142 effective in reducing uric acid levels in patients at risk of acute tumour lysis syndrome?

Conclusion

SR29142 is a well-tolerated and fast-acting treatment that effectively reduces uric acid levels in cancer patients.

Supporting Evidence

  • SR29142 led to a rapid decline of uric acid levels below measurable levels within 4 hours in all patients receiving a dose of more than 0.10 mg kg-1.
  • Preliminary results from 63 patients showed a marked decline in uric acid levels in 62 patients after the first dose of SR29142.
  • Patients treated with Uricozyme had a greater decrease in plasma uric acid levels compared to those treated with allopurinol.

Takeaway

This study shows that a new treatment can quickly lower high uric acid levels in cancer patients, helping them start chemotherapy faster.

Methodology

A phase I, single-centre, open-label trial was conducted with 28 healthy male volunteers receiving varying doses of SR29142.

Limitations

The study primarily involved healthy volunteers, and results in patients may vary.

Participant Demographics

28 healthy male volunteers participated in the trial.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication